Investor Presentaiton
Drug Discovery & Development Solutions - 9M'FY20
Particulars¹
9M'FY19 9M'FY20
% Change
Revenue
149
176
18%
Drug Discovery Services
149
176
18%
Proprietary Drug Discovery
0
0
Reported EBITDA
19
39
108%
Drug Discovery Services
19
50
168%
•
Proprietary Drug Discovery
0
(11)
Reported EBITDA Margin (%)
Drug Discovery Services
12.5%
22.0%
12.5%
28.3%
Geography Wise Revenue¹
131
106
36 40
3 2
4 4
India
North America Europe & Japan
ROW
9M'FY19
■9M'FY20
1. All figures are in Rs Crore unless otherwise stated
■ DDDS segment revenue increased 18% YoY to Rs 176 Crore led
by growth in Drug Discovery Services business, which was
driven by higher demand from Biotech companies for
Integrated Services, DMPK, Chemistry & Scale-up.
Revenue from North America increased by 24% YoY
■ EBITDA at Rs 39 Crore a YoY increase of 108%
Drug Discovery Services EBITDA increased to Rs 50 Crore up
168% YoY. Margin improvement to 28.3% from 12.5% in
9M'FY19
JUBILANT
LIFESCIENCESView entire presentation